Anavex Appoints Epilepsy and Clinical Trial Methodology Expert to Scientific Advisory Board

NEW YORK, NY –March 12, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced the appointment of Jacqueline French, MD, FAAN, to the Company’s Scientific Advisory Board.…